Skip to main content
SpringerLink
Log in

Fast-Acting Antidepressants

Can the Need be Met?

  • Review Articles
  • Drug Therapy
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Preclinical studies suggest that downregulation of β-adrenoceptors in the CNS in animals can be achieved with short term administration of high doses of antidepressants. Similarly, the function of the serotonergic system has been shown in preclinical studies to undergo rapid changes during antidepressant administration. However, the relevance of these observations to clinical antidepressant effects remains speculative.

While manipulation of these 2 neurotransmitter systems has provided the rationale for several strategies for ‘rapid onset’ antidepressants, other neurotransmitter systems are undoubtedly involved in the mechanism of action. Dopaminergic, peptidergic and glucocorticoid receptors may provide a new focus for the rapid onset of antidepressant action.

Nevertheless, some clinical studies with existing agents suggest that antidepressant responses in patients are evident within 1 week of the commencement of treatment. The limiting step in achieving such a rapid onset may be the drug doses required. Intolerance to the adverse effects precludes the use of the high doses needed. There is, therefore, a need to develop drugs with less troublesome adverse effects in order to test the hypothesis that high therapeutic doses of antidepressants may lead to a rapid clinical response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smith AL, Weissman MM. Epidemiology. In: Paykel E, editor. Handbook of affective disorders. Edinburgh: Churchill Livingstone, 1992; 111–29

    Google Scholar 

  2. Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry 1970; 117: 437–48

    Article  PubMed  CAS  Google Scholar 

  3. Pokorny AD. Prediction of suicide in psychiatric patients: report of a prospective study. Arch Gen Psychiatry 1983; 40: 249–57

    Article  PubMed  CAS  Google Scholar 

  4. Grahame-Smith DG. Serotonin in affective disorders. Int Clin Psychopharmacol 1992; 6 Suppl. 4: 5–13

    Article  PubMed  Google Scholar 

  5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62

    Article  PubMed  CAS  Google Scholar 

  6. Snaith P. What do depression rating scales measure? Br J Psychiatry 1993; 163: 293–8

    Article  PubMed  CAS  Google Scholar 

  7. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9

    Article  PubMed  CAS  Google Scholar 

  8. Prien RF, Levine J. Research and methodological issues for evaluating the therapeutic effectiveness of antidepressant drugs. Psychopharmacol Bull 1984; 20: 250–7

    PubMed  CAS  Google Scholar 

  9. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981; 38: 1160–80

    Article  PubMed  CAS  Google Scholar 

  10. Sulser F, Betulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978; 27: 257–61

    Article  PubMed  CAS  Google Scholar 

  11. Garattini S, Samanin R. Biochemical hypothesis on antidepressant drugs: a guide for clinicians or a toy for pharmacologists? Psychol Med 1988; 18: 287–304

    Article  PubMed  CAS  Google Scholar 

  12. Pilc A, Enna SJ. Synergistic interaction between α- and β-ad-renergic receptors in rat brain slices: possible site for antidepressant drug action. Life Sci 1985; 37: 1183–94

    Article  PubMed  CAS  Google Scholar 

  13. Sugrue MF. Do antidepressants possess a common mechanism of action? Biochem Pharmacol 1983; 32: 1811–7

    Article  PubMed  CAS  Google Scholar 

  14. Brunello N, Barbaccia ML, Chuang D-M, et al. Down-regulation of β-adrenergic receptors following repeated injections of desmethylimipramine: permissive role of serotonergic axons. Neuropharmacology 1982; 21: 1145–9

    Article  PubMed  CAS  Google Scholar 

  15. Norman TR, Judd FK, Burrows GD. New pharmacological approaches to the treatment of depression: from theory to clinical practice. Aust NZ J Psychiatry 1992; 26: 73–81

    Article  CAS  Google Scholar 

  16. Scott JA, Crews FT. Rapid decrease in rat brain beta adrenergic receptor binding during combined antidepressant alpha-2 antagonist treatment. J Pharm Exp Ther 1983; 224: 640–6

    CAS  Google Scholar 

  17. Baron BM, Ogden A-M, Siegel BW, et al. Rapid down-regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988; 154: 125–34

    Article  PubMed  CAS  Google Scholar 

  18. Asakura M, Tsukamoto T, Kubota H, et al. Role of serotonin in the regulation of β-adrenoceptors by antidepressants. Eur J Pharmacol 1987; 141: 95–100

    Article  PubMed  CAS  Google Scholar 

  19. Shopsin B, Friedman E, Gershon S. The use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975; 1: 239–47

    PubMed  CAS  Google Scholar 

  20. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976; 33: 811–9

    Article  PubMed  CAS  Google Scholar 

  21. Miller HL, Delgado PL, Salomon RM, et al. Acute tryptophan depletion: a method of studying antidepressant action. J Clin Psychiatry 1992; 53 Suppl. 10: 28–35

    PubMed  Google Scholar 

  22. De Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry 1990; 51 Suppl. B: 4–8

    PubMed  Google Scholar 

  23. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990; 51 Suppl. 4: 14–20

    PubMed  Google Scholar 

  24. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51: 248–51

    Article  PubMed  CAS  Google Scholar 

  25. Hoyer D, Middlemiss DN. The pharmacology of the terminal 5HT autoreceptors in mammalian brain: evidence for species differences. Trends Pharmacol Sci 1989; 10: 130–2

    Article  PubMed  CAS  Google Scholar 

  26. Miquel MC, Hamon M. 5HT1 receptor subtypes: pharmacological heterogeneity. In: Langer SZ, Brunello N, Racagni G, et al., editors. Serotonin receptor subtypes: pharmacological significance and clinical implications. Basel: Krager, 1992: 13–30

    Google Scholar 

  27. Briley M, Moret C. 5HT and antidepressants: in vitro and in vivo release studies. Trends Pharmacol Sci 1993; 14: 396–7

    Article  PubMed  CAS  Google Scholar 

  28. Bouckoms A, Mangini L. Pergolide: an antidepressant adjustment for mood disorders? Psychopharmacol Bull 1993; 29: 207–11

    PubMed  CAS  Google Scholar 

  29. Oades RD. The role of noradrenaline in turning and dopamine in switching between signals in the CNS. Neurosci Biobehav Rev 1985; 9: 261–82

    Article  PubMed  CAS  Google Scholar 

  30. Muscat R, Sampson D, Willner P. Dopaminergic mechanism of imipramine action in an animal model of depression. Biol Psychiatry 1990; 28; 223–40

    Article  PubMed  CAS  Google Scholar 

  31. Snaith P. Ahedonia: a neglected symptom of psychopathology. Psychol Med 1993; 23: 957–66

    Article  PubMed  CAS  Google Scholar 

  32. Sachar E. Disorders of feeling: affective disorders. In: Kandel E, Schwatz JF, editors. Principles of neural science. New York: Elsevier, 1985: 717–26

    Google Scholar 

  33. Wise RW. Catecholamine theories of reward: a critical review. Brain Res 1978; 152: 215–47

    Article  PubMed  CAS  Google Scholar 

  34. Dilsaver SC, Coffman JA. Cholinergic hypothesis of depression: a reappraisal. J Clin Psychopharmacol 1989; 9: 173–9

    Article  PubMed  CAS  Google Scholar 

  35. Meyerson LR, Wennogle LP, Abel MS, et al. Human brain receptors alterations in suicide victims. Pharmacol Biochem Behav 1992; 17: 159–63

    Article  Google Scholar 

  36. Zanko MT, Biegon A. Increased adrenergic receptor binding in human frontal cortex of suicide victims [abstract]. Soc Neurosci Abs 1983; 9: 719

    Google Scholar 

  37. Mann JJ, Stanley M. Psychobiology of suicidal behaviour. New York: New York Academy of Sciences, 1983

    Google Scholar 

  38. Healy D, O’Halloran A, Carney PA, et al. Peripheral adrenoceptors and serotonin receptors in depression. Changes associated with response to treatment with trazodone or amitriptyline. J Affect Disord 1985; 9: 285–96

    Article  PubMed  CAS  Google Scholar 

  39. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression. Implications for the β-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 1986; 43: 1155–61

    Article  PubMed  CAS  Google Scholar 

  40. Pinder RM, Wieringa JH. Third-generation antidepressants. Med Res Rev 1993; 13: 259–325

    Article  PubMed  CAS  Google Scholar 

  41. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303–7

    Article  PubMed  CAS  Google Scholar 

  42. Vandel S, Bertschy G, Bonin B, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 1992; 25: 202–7

    Article  PubMed  CAS  Google Scholar 

  43. Weilburg JP, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 1993; 3: 209–13

    Article  Google Scholar 

  44. Montgomery SA. Venlafaxine: a new dimension in antidepressant therapy. J Clin Psychiatry 1993; 54: 119–26

    Google Scholar 

  45. Wong DT, Bymaster DP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993; 8: 23–33

    PubMed  CAS  Google Scholar 

  46. de Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry 1983; 40: 1327–34

    Article  PubMed  Google Scholar 

  47. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983; 40: 1335–42

    Article  PubMed  CAS  Google Scholar 

  48. Norman TR, Sartor DM, McIntyre IM. Clinical and experimental studies on the potentiation of antidepressant drugs by thyroid hormones. Med Sci Res 1988; 16: 545–50

    CAS  Google Scholar 

  49. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989; 50: 385–8

    PubMed  CAS  Google Scholar 

  50. O’Flanagan PM. Aclomipramine (Anafranil) infusion unit. J Int Med Res 1973; 1: 375–81

    Google Scholar 

  51. Pollock BG, Perel JM, Nathan S, et al. Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Arch Gen Psychiatry 1989; 46: 29–35

    Article  PubMed  CAS  Google Scholar 

  52. Escobar JI, Flemenbaum A, Schiele BC. Chlorimipramine: a double-blind comparison of intravenous versus oral administration in depressed patients. Psychopharmacologia 1973; 33: 111–6

    Article  PubMed  CAS  Google Scholar 

  53. Sethy VH, Day JS, Cooper MM. Rapid changes in central beta-adrenergic receptors after chronic intravenous infusion of antidepressants. Res Commun Chem Pathol Pharmacol 1986; 54: 35–46

    PubMed  CAS  Google Scholar 

  54. Kilts CD, Bissette G, Krishman KRR, et al. The preclinical and clinical neurobiology of corticotropin releasing factor (CRF). In: Halbreich U, editor. Hormones and depression. New York: Raven Press, 1987: 297–311

    Google Scholar 

  55. Nemeroff CB, Widerlov E, Brisette G, et al. Elevated concentrations of CSF corticotropin releasing factor-like immunore-activity in depressed patients. Science 1984; 226: 1342–4

    Article  PubMed  CAS  Google Scholar 

  56. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. II. Discrimination of depressed from non-depressed patients. Arch Gen Psychiatry 1976; 33: 1051–8

    Article  PubMed  CAS  Google Scholar 

  57. Gold PW, Kling MA, Kellner CH, et al. Corticotropin-releasing hormone: relevance to normal physiology and to the pathophysiology of depression and anorexia nervosa. In: Halbreich U, editor. Hormones and depression. New York: Raven Press, 1987: 77–89

    Google Scholar 

  58. Greden JF, Gardner R, King D, et al. Dexamethasone suppression tests in antidepressants treatment of melancholia — the process of normalisation and test-retest reproducibility. Arch Gen Psychiatry 1983; 40: 493–500

    Article  PubMed  CAS  Google Scholar 

  59. Pepin M-C, Beautieu S, Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol Brain Res 1989; 6: 77–83

    Article  PubMed  CAS  Google Scholar 

  60. Liposits Z, Phelix C, Pauli WK. Synaptic interactions of serotonergic axons and CRF synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. Histochemistry 1987; 86: 541–9

    Article  PubMed  CAS  Google Scholar 

  61. Dinan TG. Glucocorticoids and the genesis of depressive illness: a psychobiological model. Br J Psychiatry 1994; 164: 365–71

    Article  PubMed  CAS  Google Scholar 

  62. Wolkowitz OM, Reus VI, Manfredi F, et al. Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 1993; 150: 810–2

    PubMed  CAS  Google Scholar 

  63. Murphy BEP, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993; 18: 209–13

    PubMed  CAS  Google Scholar 

  64. Alexopoulos GS, Inturrisi CE, Lipmann R, et al. Plasma immuno reactive beta endorphin levels in depression. Effect of electroconvulsive therapy. Arch Gen Psychiatry 1983; 40: 181–3

    Article  PubMed  CAS  Google Scholar 

  65. Nakata Y, Chang KJ, Mitchell CL, et al. Repeated electroshock down regulates the opioid receptors in rat brain. Brain Res 1985; 346: 160–3

    Article  PubMed  CAS  Google Scholar 

  66. De Filipe MC, Jimencez I, Castro A, et al. Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases. Eur J Pharmacol 1989; 159: 175–80

    Article  Google Scholar 

  67. Feinmann C. Pain-relief by antidepressants. Possible modes of action. Pain 1985; 23: 1–8

    Article  PubMed  CAS  Google Scholar 

  68. Frazer A, Lucki I, Sills M. Alterations in monoamine-containing neuronal function due to administration of antidepressants repeatedly to rats. Acta Pharmacol Toxicol 1985; 56 Suppl. 1: 21–34

    CAS  Google Scholar 

  69. Caldecott-Hazard S, Morgan DG, De Leon-Jones F, et al. Clinical and biochemical aspects of depressive disorders. II. Transmitter receptors theories. Synapse 1991; 9: 251–301

    Article  PubMed  CAS  Google Scholar 

  70. Lesch KP, Lerer B. The 5HT-receptor-G protein-effector system complex in depression I. Effect of glucocorticoids. J Neural Transm Gen Sect 1991; 84: 3–18

    Article  PubMed  CAS  Google Scholar 

  71. Sulser F, Sanders-Bush E. The serotonin-norepinephrine link hypothesis of affective disorders: receptor-receptor interactions in brain. In: Erlich YH, Erlich RH, Lenox E, et al., editors. Molecular basis of neuronal responsiveness. New York: Plenum Press, 1987: 487–502

    Google Scholar 

  72. Sulser F. New perspective on the molecular pharmacology of affective disorders. Eur Arch Psychiatry Neurol Sci 1989; 238: 231–9

    Article  PubMed  CAS  Google Scholar 

  73. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987; 17: 297–309

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, 3084, Victoria, Australia

    Trevor R. Norman

  2. Department of Pharmacology, University College Galway, Galway, Ireland

    Brian E. Leonard

Authors
  1. Trevor R. Norman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian E. Leonard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Norman, T.R., Leonard, B.E. Fast-Acting Antidepressants. CNS Drugs 2, 120–131 (1994). https://doi.org/10.2165/00023210-199402020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199402020-00005

Keywords

Search

Navigation